3,129
Views
0
CrossRef citations to date
0
Altmetric
Original Research

The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey

, , , , , , , , , & show all
Pages 1199-1213 | Received 20 Jul 2022, Accepted 17 Aug 2022, Published online: 21 Sep 2022

Figures & data

Figure 1. Survey responses by study population.

Overall participants, n = 405. aFamily members who acted as proxies and completed the survey on behalf of patients aged <13 years could also participate themselves as family members and were included in both the patient and family member populations; bParents/legal guardians who were not primary caregivers; cSiblings were aged ≥18 years.
Figure 1. Survey responses by study population.

Table 1. Burden of illness survey participant demographics.

Figure 2. a) Joint mobility by patient age group b) Impact of joint mobility on patients’ physical functioning.

Patient population, n = 219. Missing data may result in n values for a category not totaling to the N value of the given population. PRMA levels are derived from PRMA total scores: total score 0–6, Level 1; total score 7–12, Level 2; total score 13–18, Level 3; total score ≥19, Level 4. A higher total score/PRMA level represents more severe limitations in mobility; Percentage of worst possible score is created from total score (to account for differences in scoring in the adult and pediatric assessments) to allow for a combined analysis of FOP-PFQ across all participants; higher scores on the FOP-PFQ indicate greater difficulty with activities of daily living and physical functioning. FOP: fibrodysplasia ossificans progressiva; FOP-PFQ: FOP Physical Function Questionnaire; PRMA: Patient-Reported Mobility Assessment; SD: standard deviation.
Figure 2. a) Joint mobility by patient age group b) Impact of joint mobility on patients’ physical functioning.

Figure 3. Impact of joint mobility on QoL for patients, family members, and primary caregivers.

Patient population (≥13 years), n = 161 (only patients aged ≥13 years are included); family member population, n = 167 (family members included primary caregivers, non-primary caregivers, and siblings aged ≥18 years); primary caregiver population, n = 114. The dashed vertical line separates the patient population from the family member population and the primary caregiver subpopulation. Missing data may result in n values for a category not totaling to the N value of the given population. The EQ-5D-5L index score is a single-number utility score calculated using the U.S. algorithm. The EQ-5D-5L index score, representing an individual’s quality of life according to the preferences of the general population, ranged from 0 (a health state equivalent to dead) to 1 (full health); PRMA levels are derived from PRMA total scores: total score 0–6, Level 1; total score 7–12, Level 2; total score 13–18, Level 3; total score ≥19, Level 4. A higher total score/PRMA level represents more severe limitations in mobility. EQ-5D-5L: EuroQoL health-related quality of life questionnaire; PRMA: Patient-Reported Mobility Assessment; QoL: quality of life; SD: standard deviation.
Figure 3. Impact of joint mobility on QoL for patients, family members, and primary caregivers.

Figure 4. a) Impact of joint mobility on QoL for patients 5–14 years of age b) Impact of joint mobility on QoL for patients ≥15 years of age.

Patient population: 5–14 years, n = 57; ≥15 years, n = 148. Missing data may result in n values for a category not totaling to the N value of the given population. T-scores are calculated from raw total scores, with higher T-score values indicating better physical/mental health; PRMA levels are derived from PRMA total scores: total score 0–6, Level 1; total score 7–12, Level 2; total score 13–18, Level 3; total score ≥19, Level 4. A higher total score/PRMA level represents more severe limitations in mobility. PRMA: Patient-‍Reported Mobility Assessment; PROMIS: Patient-Reported Outcomes Measurement Information System; QoL: quality of life; SD: standard deviation.
Figure 4. a) Impact of joint mobility on QoL for patients 5–14 years of age b) Impact of joint mobility on QoL for patients ≥15 years of age.

Figure 5. a) Most commonly utilized health services within the past 12 months b) Utilization of aids, assistive devices and adaptations and medical therapies/doctors.

Patient population, n = 219. Missing data may result in n values for a category not totaling to the N value of the given population. PRMA levels are derived from PRMA total scores: total score 0–6, Level 1; total score 7–12, Level 2; total score 13–18, Level 3; total score ≥19, Level 4. A higher total score/PRMA level represents more severe limitations in mobility. a) All remaining health services were used by <24% of patients. b) Living adaptation categories: Mobility, daily activities and/or pay for assistance (4 items): mobility aids/devices, paid/unpaid assistants, personal care tools, eating tools; Bedroom, bathroom, home (3 items): bathroom aids/devices, bedroom aids/devices, home adaptations; Workplace, technology (2 items): workplace adaptations, technology adaptations; School/sport (2 items): sport adaptations, school adaptations; Medical therapies/doctors (7 items): medical therapies, doctor/nurse consultation for FOP flare-ups, respiratory/lung infections, heart failure symptoms, chronic lung disease, health services for pressure ulcers, falls. PRMA: Patient-‍Reported Mobility Assessment; SD: standard deviation.
Figure 5. a) Most commonly utilized health services within the past 12 months b) Utilization of aids, assistive devices and adaptations and medical therapies/doctors.
Supplemental material

Supplemental Material

Download Zip (3.2 MB)